Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry.
Sci Rep
; 11(1): 15097, 2021 07 23.
مقالة
ي الانجليزية
| MEDLINE | ID: covidwho-1322503
ABSTRACT
There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5-71.5%, range 0-100%) and decreased to 0.3% (IQR 0-5.4%, range 0-100%) by May and June and 0% (IQR 0-1.3%, range 0-36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care.
النص الكامل:
متاح
مجموعة:
قواعد البيانات الدولية
قاعدة البيانات:
MEDLINE
الموضوع الرئيسي:
Cardiovascular Diseases
/
Antirheumatic Agents
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
نوع الدراسة:
دراسات تجريبية
/
دراسة مبنية على المشاهدة
/
دراسة النذير
/
التجارب المعشاة ذات الشواهد
المواضيع:
لونغ كوفيد
المحددات:
كبير في السن
/
أنثى
/
البشر
/
ذكر
/
منتصف العمر
اللغة:
الانجليزية
مجلة:
Sci Rep
السنة:
2021
نوع:
مقالة
بلد الانتماء:
S41598-021-94203-7
المراجع ذات الصلة
MEDLINE
...
LILACS
LIS